Seth Klarman, who has managed the Baupost Group hedge fund since its founding 33 years ago, is a legendary value investor. A sign of the esteem in which he is held is that Margin of Safety, which he wrote in 1991, has become a cult classic. Warren Buffett is rumored to keep a copy near his desk; if you want your own copy, the book, which is out of print, will set you back $1,940 on Amazon. So it has come as something of a shock to Klarman’s bargain-hunting devotees that their hero has emerged in recent years as a wildly successful investor in biotechnology stocks. Biotech? Buffett never touches the stuff. What does Klarman see that the master doesn’t?
Klarman, whose hedge fund today manages $29 billion, wouldn’t respond to questions. But a comment in a letter he sent to his shareholders last year suggests that he has changed with the times. When he sent the letter, he had just quintupled his money in Idenix, a maker of hepatitis C drugs, after it was acquired by Merck, and the biotech portion of his stock portfolio had swollen to 37%. Wrote Klarman: “I am … pleased that this old dog (your Portfolio Manager) is still open (I’m always cautious but open) to learning a few new tricks.”
Klarman was prescient in recognizing that the genomics revolution would supercharge the biotech industry, radically improving the odds of creating successful new drugs. As young biotech firms developed exciting new compounds, larger companies would fight over them, eventually offering billions of dollars for companies that did not yet even have drugs on the market.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
That insight paid off big for Klarman and other biotech investors. Over the past five years, iShares Nasdaq Biotechnology (symbol IBB (opens in new tab)), an exchange-traded fund that tracks the sector, returned a whopping 30.7% annualized, more than twice the gain of Standard & Poor’s 500-stock index.
At the end of 2014, Baupost Group owned seven biotech stocks: Atara Biotherapeutics (ATRA (opens in new tab), $40), Forward Pharma (FWP (opens in new tab), $30), Keryx Biopharmaceuticals (KERX (opens in new tab), $11), Kindred Biosciences (KIN (opens in new tab), $7), Paratek Pharmaceuticals (PRTK (opens in new tab), $26), Theravance (THRX (opens in new tab), $17) and Theravance Biopharma (TBPH (opens in new tab), $17). (My fund owns Atara, Forward and Paratek; share prices are as of May 1.)
Klarman often reduces risk by picking stocks that give him several ways to win. Consider Forward Pharma. The Danish firm says it patented its version of dimethyl fumarate (DMF), a drug for treating multiple sclerosis, before rival Biogen did. But only Biogen is selling the drug, called Tecfidera; annual sales are running at a rate of more than $3.2 billion a year. Forward, which is challenging Biogen, was told that it would get a patent in Europe in late May and has received a favorable initial patent-interference ruling from U.S. authorities. Plus, a company official tells me, Forward’s version of DMF releases the drug more slowly than Biogen’s, resulting in fewer side effects.
Quadruple threat. Forward, whose shares have rocketed 72% since going public last October, could win in four ways. It could receive royalties on sales of Tecfidera. Biogen could buy it. Forward’s timed-release drug could turn out to be a hit. A large company could buy a big stake in Forward.
Atara has been another huge winner for Klarman. He bought in when the South San Francisco company was still private, and the stock has nearly quadrupled since Atara went public at $11 last October. Moreover, Baupost nearly doubled its stake in late March. Why the enthusiasm? Atara is working on drugs to treat different kinds of cancers and drugs to stem muscle loss.
So has Klarman really found the secret for making biotech investing safe? The answer is a qualified yes. Just own a portfolio of companies with proven technology and multiple ways to win.
-
-
Jobs Report Shows Massive Hiring in January: What the Experts Are Saying
Jobs Report Market pros weigh in on the whopping 517,000 new jobs created last month – and a drop in the unemployment rate to 1969 levels.
-
Which Charitable Giving Archetype Are You?
Understanding the charitable giving archetype that resonates with you can make it easier to align your giving with the difference you most want to make.
-
10 Things You Must Know About Becoming a Millionaire
wealth creation Think you are a millionaire in the making? Read on to see what it takes to be truly destined for wealth.
-
Why This Hedge-Fund Manager Is Shutting Down
investing Now I plan to invest a chunk of the family portfolio in index funds—oh, the horror!
-
Know When to Sell a Stock
investing Don't let a stock's stumbles blind you to its long-term potential.
-
Profit from Following Activist Investors
investing When investors like Carl Icahn and Bill Ackman turn the heat on management, shareholders stand to benefit.
-
Doubling Down on a Falling Stock
stocks Buying more shares makes sense when nothing about a company has changed except the price of its stock.
-
Andrew Feinberg's 6 Stock Picks for 2015
investing Bank of America has made great progress in cutting costs and settling legal claims for shoddy mortgage securities.
-
Promising Bargains in Biotech Stocks
investing What I like about BioDelivery Sciences is not so much that there are many ways to win as that there are almost no ways to lose.
-
Time-Tested Advice for Long-Term Investors
investing Learn from the Kahns, ultra-patient (and successful) value investors who often hold stocks for 20 years.
